aztreonam has been researched along with Infant, Premature, Diseases in 10 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
Infant, Premature, Diseases: Diseases that occur in PREMATURE INFANTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to study serum concentration and urinary concentration (urinary recovery rate) of aztreonam (AZT), AZT was administered via intravenous bolus injection at dose levels of 10 mg/kg, 20 mg/kg and 50 mg/kg to 7 cases of 4 to 26 days old mature or premature infants nearing cure-stage of various bacterial infections upon the treatment with AZT." | 3.68 | [Pharmacokinetic and clinical evaluation of aztreonam in neonates and premature infants]. ( Kawamura, K; Nakamura, H; Seo, K; Sugita, M; Toyonaga, Y, 1990) |
| "Treatment with vancomycin and aztreonam was associated with a rapid quantitative reduction in faecal colonisation with enterobacteriaceae, whereas there was no quantitative reduction in colonisation with enterobacteriaceae associated with treatment with vancomycin and gentamicin." | 2.67 | Enterobacteriaceae and neonatal necrotising enterocolitis. ( Langdale, V; Levene, M; MacKay, P; Martin, C; Millar, MR, 1992) |
| "Aztreonam (AZT) was studied for its pharmacokinetics, clinical effect and effect on intestinal bacterial flora in neonates, and the results obtained are summarized as follows: 1." | 1.28 | [Pharmacokinetic and clinical studies on aztreonam in neonates and premature infants]. ( Akita, H; Ishizuka, Y; Iwata, S; Oikawa, T; Saito, N; Sato, Y; Sunakawa, K, 1990) |
| " Average daily dosage of AZT 46." | 1.28 | [Pharmacokinetic and clinical evaluations of aztreonam monotherapy and aztreonam and ampicillin combination therapy in neonates and premature infants]. ( Aramaki, M; Kawakami, A; Koga, T; Motohiro, T; Oda, K; Sakata, Y; Shimada, Y; Tanaka, K; Tominaga, K; Tomita, S, 1990) |
| " Serum half-life was 3." | 1.28 | [Pharmacokinetics and clinical studies of aztreonam in neonates and premature infants]. ( Fukuda, M; Inoguchi, S; Tanaka, H; Tsuji, Y, 1990) |
| "Aztreonam (AZT) was administered to immature infants, neonates and infants for preclinical and clinical studies." | 1.28 | [Preclinical and clinical studies on aztreonam in pediatric surgery]. ( Kimura, K; Miyano, T; Shimomura, H, 1990) |
| "Aztreonam was administered to 25 neonates (16 term, 9 premature) with clinically and bacteriologically proved gram-negative infections." | 1.28 | Successful response of severe neonatal gram-negative infection to treatment with aztreonam. ( Constantopoulos, A; Loupa, H; Papoulias, G; Thomaidou, L, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 9 (90.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blahová, J | 1 |
| Hupková, M | 1 |
| Králiková, K | 1 |
| Krcméry, V | 1 |
| Lísková, A | 1 |
| Kubonová, K | 1 |
| Millar, MR | 1 |
| MacKay, P | 1 |
| Levene, M | 1 |
| Langdale, V | 1 |
| Martin, C | 1 |
| Fuji, R | 2 |
| Hashira, S | 2 |
| Tajima, T | 2 |
| Meguro, H | 2 |
| Abe, T | 2 |
| Sakata, H | 2 |
| Kakehashi, H | 2 |
| Fujita, K | 2 |
| Murono, K | 2 |
| Kaeriyama, M | 2 |
| Sunakawa, K | 1 |
| Ishizuka, Y | 1 |
| Saito, N | 1 |
| Akita, H | 1 |
| Iwata, S | 1 |
| Sato, Y | 1 |
| Oikawa, T | 1 |
| Toyonaga, Y | 1 |
| Sugita, M | 1 |
| Nakamura, H | 1 |
| Kawamura, K | 1 |
| Seo, K | 1 |
| Motohiro, T | 1 |
| Oda, K | 1 |
| Aramaki, M | 1 |
| Kawakami, A | 1 |
| Tanaka, K | 1 |
| Koga, T | 1 |
| Shimada, Y | 1 |
| Tomita, S | 1 |
| Sakata, Y | 1 |
| Tominaga, K | 1 |
| Tanaka, H | 1 |
| Fukuda, M | 1 |
| Inoguchi, S | 1 |
| Tsuji, Y | 1 |
| Shimomura, H | 1 |
| Miyano, T | 1 |
| Kimura, K | 1 |
| Constantopoulos, A | 1 |
| Thomaidou, L | 1 |
| Loupa, H | 1 |
| Papoulias, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Study to Assess the Safety and Immunogenicity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic (ASCI) Combined With Infusions of ex Vivo Regulatory T Cells Depleted T Lymphocytes in in Vivo Regulatory T Cells Depleted Patients as [NCT01513109] | Phase 1/Phase 2 | 20 participants (Anticipated) | Interventional | 2011-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for aztreonam and Infant, Premature, Diseases
| Article | Year |
|---|---|
Enterobacteriaceae and neonatal necrotising enterocolitis.
Topics: Aztreonam; Drug Therapy, Combination; England; Enterobacteriaceae Infections; Enterocolitis, Pseudom | 1992 |
[Pharmacokinetics and clinical studies on aztreonam in neonates and premature infants (the first report). Study on effectiveness and safety in mono-therapy with aztreonam. A study of aztreonam in the Perinatal Co-research Group].
Topics: Age Factors; Aztreonam; Bacterial Infections; Birth Weight; Clinical Trials as Topic; Female; Half-L | 1990 |
[Pharmacokinetics and clinical studies on aztreonam in neonates and premature infants (the second report). Study on effectiveness and safety in combination therapy using aztreonam and ampicillin. A study of aztreonam in the Perinatal Co-research Group].
Topics: Ampicillin; Aztreonam; Bacterial Infections; Clinical Trials as Topic; Drug Therapy, Combination; Fe | 1990 |
7 other studies available for aztreonam and Infant, Premature, Diseases
| Article | Year |
|---|---|
Transfer of resistance to oxy-imino-cephalosporins and of extended-spectrum beta-lactamase productions in Klebsiella pneumoniae strains from infected neonates.
Topics: Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cefotaxime; Ceftazidime; Cephalosporin Resistanc | 1998 |
[Pharmacokinetic and clinical studies on aztreonam in neonates and premature infants].
Topics: Ampicillin; Aztreonam; Bacterial Infections; Drug Evaluation; Drug Therapy, Combination; Female; Hum | 1990 |
[Pharmacokinetic and clinical evaluation of aztreonam in neonates and premature infants].
Topics: Ampicillin; Aztreonam; Bacterial Infections; Drug Evaluation; Drug Therapy, Combination; Female; Hum | 1990 |
[Pharmacokinetic and clinical evaluations of aztreonam monotherapy and aztreonam and ampicillin combination therapy in neonates and premature infants].
Topics: Ampicillin; Aztreonam; Bacterial Infections; Drug Evaluation; Drug Therapy, Combination; Female; Hum | 1990 |
[Pharmacokinetics and clinical studies of aztreonam in neonates and premature infants].
Topics: Ampicillin; Aztreonam; Bacterial Infections; Drug Evaluation; Drug Therapy, Combination; Female; Hal | 1990 |
[Preclinical and clinical studies on aztreonam in pediatric surgery].
Topics: Aztreonam; Bacterial Infections; Bile; Biliary Atresia; Female; Humans; Infant, Newborn; Infant, Pre | 1990 |
Successful response of severe neonatal gram-negative infection to treatment with aztreonam.
Topics: Aztreonam; Bacterial Infections; Gram-Negative Bacteria; Humans; Infant, Newborn; Infant, Premature, | 1989 |